762260-63-9

Basic information

• Product Name: 7-broMo-1,2-dihydro-2-oxoquinoline-4-carboxylic acid
• Synonyms: 7-broMo-1,2-dihydro-2-oxoquinoline-4-carboxylic acid;7-BroMo-2-oxo-1,2-dihydroquinoline-4-carboxylic acid;7-BROMO-2-OXO-1,2-DIHYDROQUINOLINE-4-CARBOXYLIC ACID(WXC08037)
• CAS NO: 762260-63-9
• Molecular Formula: C₁₀H₆BrNO₃
• Molecular Weight: 268.06354
• Mol File: 762260-63-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-broMo-1,2-dihydro-2-oxoquinoline-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 7-broMo-1,2-dihydro-2-oxoquinoline-4-carboxylic acid(762260-63-9)
• EPA Substance Registry System: 7-broMo-1,2-dihydro-2-oxoquinoline-4-carboxylic acid(762260-63-9)

Safety Data

• Hazardous Substances Data: 762260-63-9(Hazardous Substances Data)

Upstream product

• 6326-79-0 6-bromoisatin 
• 141-82-2 malonic acid 
• 52415-29-9 6-bromo-1H-indole 

Relevant articles and documents

Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors

Checkpoint kinase 1 (Chk1, CHEK1) is a Ser/Thr protein kinase that plays a key role in mediating the cellular response to DNA-damage. Synthesis and evaluation of a previously described class of Chk1 inhibitors, triazoloquinolones/triazolones (TZs) is further described herein. Our investigation of structure-activity relationships led to the identification of potent inhibitors 14c, 14h and 16e. Key challenges included modulation of physicochemical properties and pharmacokinetic (PK) parameters to enable compound testing in a Chk1 specific hollow fiber pharmacodynamic model. In this model, 16e was shown to abrogate topotecan-induced cell cycle arrest in a dose dependent manner. The demonstrated activity of TZs in this model in combination with a chemotherapeutic agent as well as radiotherapy validates this series of Chk1 inhibitors. X-ray crystal structures (PDB code: 2YEX and 2YER) for an initial lead and an optimized analog are also presented.

Synthesis and biological evaluation of novel 2-oxo-1,2-dihydroquinoline-4-carboxamide derivatives for the treatment of esophageal squamous cell carcinoma

No new and effective treatments have been approved for the treatment of esophageal squamous cell carcinoma (ESCC) in the past decade. Cisplatin and 5-fluoruracil are the most commonly used drugs for this disease. In order to develop a new class of drugs effective in our ESCC phenotypic screens, we began a systematic approach to generate novel compounds based on the 2-oxo-1,2-dihydroquinoline-4-carboxamide fragment. Herein, we report on the synthesis and initial assessment of 55 new analogues in two ESCC cell lines. Some of the active analogues with IC50 values around 10 μM were tested in three additional cell lines. Our structure-activity relationships revealed remarkable alterations in the anti proliferative activities upon modest chemical modifications and autophagy modulation is a suggested mechanism of action.

Compounds with anti-cancer activity

Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.